Three-dimensional (3D) printing is transforming the field of pediatric otolaryngology. Nine years after implanting the first 3D bioabsorbable tracheal splint in an infant boy with severe tracheobronchomalacia (N Engl J Med. 2013;368:2043-2045), a multidisciplinary team of surgeons and biomedical engineers has successfully created a neotrachea supported by a 3D-printed scaffold to treat an infant born with tracheal agenesis, a rare congenital anomaly that’s usually fatal.
Explore This IssueFebruary 2021
“3D printing is allowing us to treat diseases that weren’t treatable before,” said Glenn Green, MD, professor of otolaryngology–head and neck surgery at the University of Michigan Medical School, Ann Arbor, and one of the lead surgeons involved in both cases. “It’s opening up new ways of making devices that are specific for individuals who have rare conditions who, if left untreated, would not survive.” The infant was the first child to undergo this procedure; she’s doing well and is already the second-longest surviving child born with this condition in the United States, Dr. Green noted.
Although there are many surgical strategies for managing tracheobronchomalacia, such as tracheostomy, tracheal resection, and slide tracheoplasty, before the advent of the 3D approach, surgeons were running out of options for treating very ill infants. The idea for creating a 3D trachea stent was born out of a conversation Dr. Green had with a colleague. “I was talking about how we had these kids whom we were unable to treat. I was introduced to Scott Hollister, PhD, an engineer, and together we developed something that has helped a lot of children.” Dr. Hollister is now a bioengineer in the Wallace H. Coulter Department of Biomedical Engineering at the Georgia Institute of Technology in Atlanta.
First implanted in 2012, the 3D-printed scaffold stent is designed to go around the outside of the diseased portion of the trachea to allow air to freely flow into the lungs (Fig. 1). To date, Dr. Green and his colleagues at the University of Michigan have treated 34 patients using the device. “We’ve taken individuals who were unable to leave the intensive care unit for months due to serious episodes of respiratory obstruction, and they’re now home with their parents. These conditions are now very treatable,” Dr. Green said.
Because the implant is porous, it creates a conductive space for blood vessels to grow. Within the first couple of weeks, the patient’s own blood vessels quickly grow into the scaffolding. —David A. Zopf, MD, MS
One of the main benefits of the device is that it’s made of a resorbable material designed to dissolve after approximately three to four years. As the tissue grows into the stent, it’s reconfigured to the shape of the scaffold. “By reconfiguring the way that the tissue grows, over time the original problem goes away,” said Dr. Green. “We now have about nine years of follow-up, and our early patients are growing and thriving.”
Dr. Green and his University of Michigan colleagues are in the process of applying for FDA approval for the splint procedure so that it can be made available to a wider group of surgeons and patients.